Tyra Biosciences SURF302 data put dabogratinib’s oral bladder cancer strategy under scrutiny
Tyra Biosciences’ dabogratinib showed encouraging single-lesion responses in SURF302, but mixed broader data sent shares sharply lower.
Pharma & Biotech